Predictive factors for low rate of remission in a population of Colombian @entity1 with severe proliferative XXXX .

@entity1 @entity644 @entity1310 @entity1252 @entity786 @entity1988 @entity618 @entity1011
UNASSIGNED: The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12  months in a group of @entity1 with proliferative @entity1988 from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with @entity1252 as defined by the American College of Rheumatology with biopsy-proven @entity1310 . We assessed 149 @entity1 , with 84  % female. Age at diagnosis of @entity1252 is 24.7  years (16-31). The time between diagnosis of @entity1252 and @entity1310 is 2  months (0-35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8  %), III (13.4  %), V   +   III (3.3  %), and V   +   IV (3.3  %). Activity index is 6.18        4.55 and chronicity index is 1 (0-3). The result of 24-h @entity644 is 2000  mg (667-4770) and baseline @entity1011 is 0.9  mg/dL (0.7-1.3). Induction therapy includes corticosteroids (100  %), @entity786 (74.1  %), and @entity618 (25.9  %). At 12  months, 40.7  % of individuals failed to attain partial or complete remission. Elevated @entity1011 (p   =   0.0001) and 24-h @entity644 greater than 1500  mg (p   =   0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline @entity1011 elevation (OR 3.62, 95  % CI, 1.59-8.23; p   =   0.002) and 24-h @entity644 greater than 1500  mg (OR 3.62, 95  % CI, 1.29-10.13; p   =   0.014) were independent predictors of failure to achieve partial or complete remission. At 12  months, 40.7  % of @entity1 did not attain partial or complete remission. Baseline elevated @entity1011 and 24-h @entity644 over 1500  mg were predictors for poor response.
